Meeder Asset Management Inc.'s holdings in Chemours Company (The) were worth $369,000 as of its most recent filing with the SEC.
UBS increased shares of Chemours (NYSE:CC) from a "Sell" rating to a "Neutral" rating in a research note shared with investors on Monday, 7 August. James Investment Research Inc. purchased a new stake in shares of Chemours Company (The) during the first quarter valued at about $505,000. Nationwide Fund Advisors now owns 413,027 shares of the specialty chemicals company's stock valued at $15,902,000 after buying an additional 299,121 shares in the last quarter. Financial Architects Inc now owns 2,940 shares of the specialty chemicals company's stock valued at $111,000 after buying an additional 2,719 shares during the period. Chemours Company (The) shares had a trading volume of 2,218K by the end of trading on Friday. Public Employees Retirement Association of Colorado now owns 39,521 shares of the specialty chemicals company's stock valued at $1,499,000 after buying an additional 5,812 shares during the period. Finally, Dimensional Fund Advisors LP raised its stake in Chemours Company (The) by 51.6% in the fourth quarter. BlackRock Inc. now owns 19,160,930 shares of the specialty chemicals company's stock worth $737,696,000 after buying an additional 19,121,339 shares during the period.
Institutional investors have recently added to or reduced their stakes in the stock.
By historical standards, The Chemours Company (NYSE:CC) remains a cheap stock.
A total of 7 analysts have released a report on Chemours Company. zero analysts rating the company a strong buy, zero analysts rating the company a buy, zero analysts rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of $9.93.
Chemours Company (The) now has a P/E ratio of 30.87 and market capitalization is 8.73B. Analysts on average have given a price target of $49.29 to The Chemours Company stock.
The stock of Chemours Co (NYSE:CC) earned "Sell" rating by UBS on Tuesday, August 9.
Looking forward, the company is expected to report earnings of $1.02 per share for the current quarter.
The stock has a Return on Assets of 4.4 percent, Return on Investment of -1.5 percent and a Return on Equity of 81.6 percent. The company's 5 year Earnings per share growth and Capital Spending growth remains at -65.59 and -0.98. The firm's revenue for the quarter was up 10.8% on a year-over-year basis. On average, analysts anticipate that Chemours Company will post $3.51 EPS for the current year. The company also declared a dividend to be paid on Friday the 15th of September 2017. The ex-dividend date will be Monday May 15th, 2017.
WARNING: This news story was published by BNB Daily and is the sole property of of BNB Daily. If you are accessing this article on another domain, it was illegally copied and republished in violation of United States & global copyright and trademark legislation. The correct version of this piece of content can be accessed at https://www.thestockobserver.com/2017/08/09/chemours-company-thes-cc-buy-rating-reaffirmed-at-jefferies-group-llc-updated-updated-updated.html. Lastly, Zacks Lowered Chemours Company (The) from a "buy" recommendation to a "hold" recommendation in a analysis note on early Wed, Jul 12th. J P Morgan Chase & Co increased their price objective on Chemours Company (The) to $55.00 and gave the stock an "overweight" rating in a research report on Friday, August 4th. UBS AG reissued a sell rating and set a $36.00 target price (up previously from $35.00) on shares of Chemours Company (The) in a research note on Wednesday, June 14th. Citigroup Inc. increased their price target on Chemours Company (The) to $59.00 and gave the stock a "buy" rating in a research note on Friday, August 4th. BidaskClub raised Chemours Company (The) from a "hold" rating to a "buy" rating in a research note on Wednesday, July 12th. Two analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. Also, VP Erich Parker unloaded 4,908 stocks of the firm's shares in a trade dated Tue, May 16th. The stock was sold at an average price of $45.53, for a total value of $223,461.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Richard H. Brown bought 2,500 shares of the business's stock in a transaction on Wednesday, May 3rd. As of the end of the quarter Federated Investors Inc /pa/ had sold a total of 52,380 shares trimming its stake by 70.0%. The short ratio in the company's stock is documented at 1 and the short float is around of 1.62%.
The Chemours Company (CC) has 185.07 Million shares outstanding and 184.04 Million shares were floated in market. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). Its products include titanium dioxide, refrigerants, industrial fluoropolymer resins and a portfolio of mining and industrial chemicals, including sodium cyanide. Fluoroproducts segment provides fluoroproducts, refrigerants and industrial fluoropolymer resins.